What is CRH's intrinsic value?

TickerWorth's valuation lenses put CRH plc (CRH) between $45.85 and $188.71 per share, versus a market price of $82.52. They disagree too widely for us to state a single fair value, so we publish the range.

Is CRH overvalued or undervalued?

At $82.52 the price sits inside a range too wide to call either way. We don't call CRH overvalued or undervalued from a range this wide. This is an educational estimate, not advice.

What discount rate is used for CRH?

A WACC of 9.6% and a terminal growth rate of 2.5%.

Is CRH stock undervalued?

TickerWorth's fair-value range for CRH plc (CRH) is $45.85 – $188.71 against a market price of $82.52. Too wide to call. We publish a range here, not one number, so we do not call it over- or undervalued. This is a model estimate, not investment advice.

CRH (CRH) DCF valuation and fair value

Our fair-value range for CRH plc (CRH) is $45.85 – $188.71, built on a 9.6% discount rate (WACC) and 2.5% terminal growth. It blends our discounted-cash-flow model with other valuation lenses. Every assumption is listed on this page with its source.

What growth is priced into CRH stock?

Today's price implies revenue growth of 8.0% a year for 5 years; our model assumes 4.0% a year on average over the same horizon. This is a reverse DCF: it holds our cash-flow model's other inputs and solves for the revenue growth that makes the model equal today's price of $82.52. A model estimate, not investment advice.

CRH (CRH) insider trading

We have no recent SEC Form 4 insider filings on file for CRH plc (CRH). Form 4 covers US-listed companies only.

CRH · Intrinsic value

Is CRH plc (CRH) overvalued or undervalued?

Name: CRH plc (CRH) DCF intrinsic value
Creator: TickerWorth

As of Oct 19, 2026, TickerWorth's valuation lenses put CRH plc (CRH) at $45.85 – $188.71, too broad a range to say where the delayed market price of $82.52 sits in it, so we do not call it over- or undervalued. It is a model estimate, and every input behind it is sourced below.

Model by Miraaj Patel · generated from a hand-researched model · Updated Oct 19, 2026 · How these pages are made

Open full CRH analysis

What is CRH worth?

Fair-value range: $45.85 – $188.71
Market price: $82.52
Gap to fair value: —
Verdict: Too wide to call

Price as of 19 Oct 2026, 13:56 UTC · Prices are delayed.Our valuation lenses disagree too widely on this company for us to publish a single number, so we publish the range instead. We do not call it over- or undervalued from a spread this wide.

Fair-value range against the delayed market price: Too wide to call.

Reverse DCF: Today's price implies revenue growth of 8.0% a year for 5 years; our model assumes 4.0% a year on average over the same horizon.

What is CRH's TickerWorth Score?

C47/100

Middle of the pack — real strengths and real weaknesses

Compared with Basic Materials companies in US

Its strongest point: trades below our estimate of what it's worth. Its weakest: recent price trend has been weak.

Value · 63 of 100
Cheaper than 63% of Basic Materials companies in US
Price vs worth · 72 of 100
Quality · 54 of 100
More profitable than 54% of Basic Materials companies in US
Financial health · 33 of 100
Financially stronger than 33% of Basic Materials companies in US
Growth · 25 of 100
Growing faster than 25% of Basic Materials companies in US
Momentum · 8 of 100
Outperformed 8% of Basic Materials companies in US over the past year

Confidence: Medium confidence · Scored 19 Oct 2026, 13:56 UTC

Get the Undervalued Company of the Week.

Where the numbers come from

Hand-researched model

What the modeller flagged

THE MODEL SITS ~18% BELOW THE MARKET, AND THE DISAGREEMENT IS MAINLY ABOUT ACQUISITIONS AND THE DISCOUNT RATE. At the house rate (5.24% Treasury + 1.191 x 5% ERP = 11.2% cost of equity; WACC 9.58%) and 2.5% perpetual growth, ~$3.6-4.9B a year of unlevered free cash flow is worth ~$61.6B of enterprise value; at today's price the market pays ~$71.3B (market cap ~$55.0B + the $16.3B bridge), ~8.6x guided 2026 Adjusted EBITDA. Holding everything else, the price needs a beta of ~0.93 (WACC ~8.6%), or ~3.7% growth forever, or a steady ~18.7% operating margin from 2027 (vs 14.5% in FY2025), or ~9.8% organic growth a year for 2027-30 with no acquisition cost.
THE AUTOMATIC MODEL'S WIDE 'UNDERVALUED' READ IS NOT REPRODUCED. We cannot see the automatic model's inputs, but the filings show two traps a generic DCF falls into here: CRH's reported revenue growth (+5.3% in FY2025) was entirely acquired - organic revenue fell ~0.7% - while the $3.9B of acquisition spend that bought it is not capex; and management's 7-9% growth target is explicitly 'including organic and inorganic growth'. Extrapolating that growth without charging for the deals overstates value. Its other likely blind spots are the minorities ($1.5B) and the seasonal mid-year balance sheet.
BETA IS THE BIGGEST SINGLE INPUT. The published 1.191 is used as is. Every 0.1 moves the value ~$5; a beta of 1.0 gives ~$78.40 and 0.9 gives ~$84.90. Aggregates businesses are often argued to deserve lower betas than their share-price history shows; this tracker does not override published betas.
TERMINAL VALUE IS ~73% OF ENTERPRISE VALUE - just under the 75% line. The implied exit multiple is only ~7.3x 2030 EBITDA (depreciation-only EBITDA), below where listed aggregates companies usually trade and below the 11.5x CRH is paying for Arcosa; that is what a 9.6% discount rate and 2.5% growth imply, and it is the clearest sign of how much more optimistic the market is about long-run growth than this model.
YEAR-1 FCF (~$3.55B) is ~22% ABOVE the last reported fiscal-year FCF ($2,912M = OCF $5,625M - capex $2,713M). The gap is mostly that the reported figure is after ~$0.72B of cash interest while the DCF's is unlevered; the rest is the guided margin step-up. It is NOT the management 'Adjusted Free Cash Flow' of $4,969M, which deducts maintenance capex only.
YEAR 1 IS ALREADY HALF REPORTED (H1 ended 2026-06-30), and seasonally it is the weak half. The bridge starts at the 2025-12-31 Net Debt so that all of FY2026's operating cash is counted once, in Year 1; the engine still discounts it a full year. The FY2026 10-K (~February 2027) re-base removes the overlap - and will have to decide how to bring Arcosa in.
THE NONCONTROLLING INTERESTS ARE AT CARRYING VALUE ($1,500M), NOT EARNINGS VALUE (~$0.7B at 15x their ~$49M share of trailing earnings). The redeemable part is carried at redemption value, and the rest was largely fair-valued when acquired, so carrying value is the filed number; the earnings basis would add ~$1.15/share.
SBC of $143M (0.4% of revenue, FY2025) is expensed inside GAAP operating income and not added back; dilution is captured by the weighted-diluted count.
No beta, tax or bridge adjustment has been made to move the answer toward the market price; the inputs are filed or guided figures except the H2 2026 revenue estimate, the Years 2-5 organic path and margins, the 6.5% capex rate, the working-capital rate and the divestiture-tax item in the bridge, which are mine.

Why CRH gets a range, not one number

At a recent price of $82.52, CRH plc (CRH) sits inside a range too wide to call either way: our valuation lenses put the business somewhere between $45.85 and $188.71 per share. They disagree too widely for us to state a single fair value. We publish the range rather than a midpoint because a number that precise would claim more than the methods can support. This is an educational model, not a price target or a recommendation.

Read the full reasoning

The valuation discounts CRH plc's projected free cash flows at a weighted-average cost of capital (WACC) of 9.6%, with a long-run terminal growth rate of 2.5%. About 73% of the enterprise value comes from the terminal value — the portion beyond the explicit forecast window — which is typical for a stable, cash-generative business and a reminder that small changes in the discount rate or terminal growth assumption swing the intrinsic value meaningfully.

Running the DCF in reverse — solving for the growth the current price already assumes — the market is implying roughly 8.0% annual revenue growth for CRH. Our base case instead compounds to about 4.0% a year over the same forecast, so the market is pricing in materially faster growth than our base case. The reverse-DCF is a quick sanity check: it reframes 'is this stock cheap?' as 'do I believe the growth the price requires?' rather than arguing over a single point estimate of fair value.

Sensitivity matters more than any single number. Across a reasonable band of discount-rate assumptions, CRH's modeled DCF value ranges from about $45.44 to $114.31 per share. If that range still sits below today's price, the market is optimistic relative to the model across the whole band; if it brackets the price, the stock is roughly fairly valued on our assumptions. Use the interactive slider to see exactly where your own cost-of-capital view lands.

How to read this page: the DCF fair value is what CRH plc would be worth if its cash flows grow as modeled and are discounted at the stated WACC. The assumptions table shows every input and its source; the reverse-DCF shows what the market believes; the sensitivity band shows how fragile the answer is. None of this is investment advice — it is a transparent, auditable framework for forming your own view of CRH's intrinsic value. Figures update as new filings and prices come in.

Every input behind CRH's DCF

Input	Value	Source
Base-year revenueCRH FY2025 10-K (accession 0001628280-26-009043, filed 2026-02-18), calendar year ended 2025-12-31; Q4/FY2025 results 8-K Ex-99.1 (accession 0001628280-26-009032): Total revenues $37,447M (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), +5.3% on FY2024's $35,572M. THE GROWTH WAS BOUGHT, NOT ORGANIC: the 10-K's analysis of change shows acquisitions +$2.2B (38 deals, $4.1B of consideration, largest Eco Material Technologies), divestitures -$0.5B, currency +$0.4B and ORGANIC revenue -$265M (Americas Materials -$73M, Americas Building -$102M, International -$90M), i.e. about -0.7%, on weather-hit volumes. History on the same tag: $29,206M FY2021, $32,723M FY2022, $34,949M FY2023, $35,572M FY2024. Mix FY2025: Americas Materials Solutions (aggregates, cement, asphalt, readymix, paving) $17,029M, Americas Building Solutions $7,122M, International Solutions (mostly Europe) $13,296M. UNCHANGED as the base - the DCF grows it by forecast.revenue_growth. CROSS-CHECK: H1 2026 revenue $18,147M, +7.0% on H1 2025's $16,962M (Q2 8-K Ex-99.1); organic +2.6% (+$449M), acquisitions +$1.0B, divestitures -$0.6B, currency +$0.36B (10-Q MD&A). Trailing twelve months to 2026-06-30: $38,632M. The base still contains the lawn and garden, construction accessories and MoistureShield businesses sold in Q2 2026 - see forecast.revenue_growth and special_cases.	$37,447,000,000	CRH FY2025 10-K (accession 0001628280-26-009043, filed 2026-02-18), calendar year ended 2025-12-31; Q4/FY2025 results 8-K Ex-99.1 (accession 0001628280-26-009032): Total revenues $37,447M (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), +5.3% on FY2024's $35,572M. THE GROWTH WAS BOUGHT, NOT ORGANIC: the 10-K's analysis of change shows acquisitions +$2.2B (38 deals, $4.1B of consideration, largest Eco Material Technologies), divestitures -$0.5B, currency +$0.4B and ORGANIC revenue -$265M (Americas Materials -$73M, Americas Building -$102M, International -$90M), i.e. about -0.7%, on weather-hit volumes. History on the same tag: $29,206M FY2021, $32,723M FY2022, $34,949M FY2023, $35,572M FY2024. Mix FY2025: Americas Materials Solutions (aggregates, cement, asphalt, readymix, paving) $17,029M, Americas Building Solutions $7,122M, International Solutions (mostly Europe) $13,296M. UNCHANGED as the base - the DCF grows it by forecast.revenue_growth. CROSS-CHECK: H1 2026 revenue $18,147M, +7.0% on H1 2025's $16,962M (Q2 8-K Ex-99.1); organic +2.6% (+$449M), acquisitions +$1.0B, divestitures -$0.6B, currency +$0.36B (10-Q MD&A). Trailing twelve months to 2026-06-30: $38,632M. The base still contains the lawn and garden, construction accessories and MoistureShield businesses sold in Q2 2026 - see forecast.revenue_growth and special_cases.
Base EBIT marginCRH Q4/FY2025 results 8-K Ex-99.1 (accession 0001628280-26-009032) + FY2025 10-K (accession 0001628280-26-009043): GAAP operating income $5,440M / revenue $37,447M = 14.53% (us-gaap:OperatingIncomeLoss). It is AFTER a $40M impairment (14.63% before it) and $45M of 'substantial acquisition-related costs', and it INCLUDES a $235M 'gain on disposal of long-lived assets' ($237M in FY2024) - CRH sells surplus land and depleted sites every year and management counts the proceeds in its own Adjusted Free Cash Flow, so it is treated as recurring; stripping it from every year would take ~$3.90/share off. Management cites a '12th consecutive year of margin expansion'; on the GAAP tag operating margin ran 11.4% FY2021, 11.6% FY2022, 12.0% FY2023, 13.8% FY2024, 14.5% FY2025 (same tag); Adjusted EBITDA margin 19.5% FY2024 to 20.5% FY2025. CROSS-CHECK H1 2026: operating income $2,041M = 11.2% of sales (11.5% in H1 2025) - H1 is seasonally weak (Q1 is a loss-making winter quarter for the Americas) and carries a $48M goodwill impairment on the construction-accessories sale; Q2 alone was 19.3% (19.0%). Operating leases: ~$0.3B a year of operating-lease cost stays inside this EBIT, consistent with leaving operating-lease liabilities out of net debt.	14.5%	CRH Q4/FY2025 results 8-K Ex-99.1 (accession 0001628280-26-009032) + FY2025 10-K (accession 0001628280-26-009043): GAAP operating income $5,440M / revenue $37,447M = 14.53% (us-gaap:OperatingIncomeLoss). It is AFTER a $40M impairment (14.63% before it) and $45M of 'substantial acquisition-related costs', and it INCLUDES a $235M 'gain on disposal of long-lived assets' ($237M in FY2024) - CRH sells surplus land and depleted sites every year and management counts the proceeds in its own Adjusted Free Cash Flow, so it is treated as recurring; stripping it from every year would take ~$3.90/share off. Management cites a '12th consecutive year of margin expansion'; on the GAAP tag operating margin ran 11.4% FY2021, 11.6% FY2022, 12.0% FY2023, 13.8% FY2024, 14.5% FY2025 (same tag); Adjusted EBITDA margin 19.5% FY2024 to 20.5% FY2025. CROSS-CHECK H1 2026: operating income $2,041M = 11.2% of sales (11.5% in H1 2025) - H1 is seasonally weak (Q1 is a loss-making winter quarter for the Americas) and carries a $48M goodwill impairment on the construction-accessories sale; Q2 alone was 19.3% (19.0%). Operating leases: ~$0.3B a year of operating-lease cost stays inside this EBIT, consistent with leaving operating-lease liabilities out of net debt.
Forecast revenue growthESTIMATEAssumption — TickerWorth's 5-year explicit forecast	5% → 4% → 4% → 4% → 4%	ESTIMATEAssumption — TickerWorth's 5-year explicit forecast
Risk-free rateUS 10Y Treasury constant maturity (FRED DGS10): 5.24% on 2026-10-01, the latest published observation when the program's models were set. Shared by every model in this tracker. ~71% of CRH's FY2025 Adjusted EBITDA came from its Americas segments and its shares and bonds are dollar-listed on the NYSE, so the US rate is the right base.	5.2%	US 10Y Treasury constant maturity (FRED DGS10): 5.24% on 2026-10-01, the latest published observation when the program's models were set. Shared by every model in this tracker. ~71% of CRH's FY2025 Adjusted EBITDA came from its Americas segments and its shares and bonds are dollar-listed on the NYSE, so the US rate is the right base.
BetaYahoo Finance 5Y-monthly beta via yfinance, read 2026-10-05: Published 5Y-monthly beta 1.191, used AS IS - no normalization, the same policy as Masco (1.294) and Caterpillar in this tracker. CRH joined the S&P 500 in 2025 (FY2025 results release), which may have changed who holds it, but nothing in the filings gives a reason to override the published figure. THE BIGGEST SINGLE LEVER: each 0.1 of beta is worth ~$5.00/share (1.091 gives ~$73.10; 1.291 ~$63.10), and a beta of ~0.93 (WACC ~8.6%) is what today's price needs - see what_market_believes.	1.19	Yahoo Finance 5Y-monthly beta via yfinance, read 2026-10-05: Published 5Y-monthly beta 1.191, used AS IS - no normalization, the same policy as Masco (1.294) and Caterpillar in this tracker. CRH joined the S&P 500 in 2025 (FY2025 results release), which may have changed who holds it, but nothing in the filings gives a reason to override the published figure. THE BIGGEST SINGLE LEVER: each 0.1 of beta is worth ~$5.00/share (1.091 gives ~$73.10; 1.291 ~$63.10), and a beta of ~0.93 (WACC ~8.6%) is what today's price needs - see what_market_believes.
Terminal growthESTIMATEAssumption — house default: House default 2.5% (roughly long-run nominal GDP), kept for comparability with every other company in this tracker. For CRH it is neither generous nor stingy: aggregates are local near-monopolies with long reserve lives and pricing that has historically run ahead of inflation, but organic volume across the portfolio has been flat to down in two of the last two full years. 3.0% adds ~$5.50/share; 2.0% takes ~$4.75 off. Must remain < WACC of 9.58%.	2.5%	ESTIMATEAssumption — house default: House default 2.5% (roughly long-run nominal GDP), kept for comparability with every other company in this tracker. For CRH it is neither generous nor stingy: aggregates are local near-monopolies with long reserve lives and pricing that has historically run ahead of inflation, but organic volume across the portfolio has been flat to down in two of the last two full years. 3.0% adds ~$5.50/share; 2.0% takes ~$4.75 off. Must remain < WACC of 9.58%.
Diluted sharesCRH Q2 2026 results 8-K Ex-99.1 income statement (accession 0001628280-26-050752) + Q2 2026 10-Q (accession 0001628280-26-050755): Q2 2026 weighted-average diluted shares 668.8M (basic 667.2M); H1 670.3M; FY2025 677.0M; 665.9M outstanding at 2026-06-30. Ordinary shares of EUR 0.32 each, listed directly on the NYSE (no ADR; the London listing is under review for delisting), so one share here is one share on the exchange. The count fell ~1.3% a year on buybacks, but CRH 'has not initiated a new tranche' since the last one completed on 2026-07-28 (year-to-date $0.7B), to fund Arcosa, so no further shrinkage is assumed. Using the weighted count is the house rule; the 665.9M outstanding would add ~$0.30/share.	669M	CRH Q2 2026 results 8-K Ex-99.1 income statement (accession 0001628280-26-050752) + Q2 2026 10-Q (accession 0001628280-26-050755): Q2 2026 weighted-average diluted shares 668.8M (basic 667.2M); H1 670.3M; FY2025 677.0M; 665.9M outstanding at 2026-06-30. Ordinary shares of EUR 0.32 each, listed directly on the NYSE (no ADR; the London listing is under review for delisting), so one share here is one share on the exchange. The count fell ~1.3% a year on buybacks, but CRH 'has not initiated a new tranche' since the last one completed on 2026-07-28 (year-to-date $0.7B), to fund Arcosa, so no further shrinkage is assumed. Using the weighted count is the house rule; the 665.9M outstanding would add ~$0.30/share.
Market priceDelayed quote · as of 2026-10-19 13:56 UTC	$82.52	Delayed quote · as of 2026-10-19 13:56 UTC

Change CRH's assumptions

The discount-rate dial and the editable model

Pro

Change growth, margin and WACC yourself — Pro (7-day free trial, card required).

Start free trial Try it on Apple

What does CRH plc do?

What does it do?

CRH plc, together with its subsidiaries, provides building materials solutions in Ireland, the United States, the United Kingdom, rest of Europe, and internationally. It operates through three segments: Americas Materials Solutions, Americas Building Solutions, and International Solutions. It operates in the Building Materials industry (Basic Materials sector), headquartered in Ireland. The company employs roughly 83,032 people.

How does it make money?

The business turns $38.6B in annual revenue into profit. Out of every $100 of sales, about $19 is left as operating profit (operating margin of 19.0%), after a 36% gross margin on the products/services it sells. After all costs, taxes and interest, 9.9% of revenue becomes bottom-line net profit.

Is it financially healthy?

Financially it looks mixed: carries modest debt (0.8× equity), comfortably covers its short-term bills (1.6× current ratio), and is currently profitable.

CRH insider trading

We have no recent SEC Form 4 insider filings on file for CRH plc. Form 4 covers US-listed companies only.

Common questions

What is CRH's intrinsic value?
TickerWorth's valuation lenses put CRH plc (CRH) between $45.85 and $188.71 per share, versus a market price of $82.52. They disagree too widely for us to state a single fair value, so we publish the range.
Is CRH overvalued or undervalued?
At $82.52 the price sits inside a range too wide to call either way. We don't call CRH overvalued or undervalued from a range this wide. This is an educational estimate, not advice.
What discount rate is used for CRH?
A WACC of 9.6% and a terminal growth rate of 2.5%.
Is CRH stock undervalued?
TickerWorth's fair-value range for CRH plc (CRH) is $45.85 – $188.71 against a market price of $82.52. Too wide to call. We publish a range here, not one number, so we do not call it over- or undervalued. This is a model estimate, not investment advice.
CRH (CRH) DCF valuation and fair value
Our fair-value range for CRH plc (CRH) is $45.85 – $188.71, built on a 9.6% discount rate (WACC) and 2.5% terminal growth. It blends our discounted-cash-flow model with other valuation lenses. Every assumption is listed on this page with its source.
What growth is priced into CRH stock?
Today's price implies revenue growth of 8.0% a year for 5 years; our model assumes 4.0% a year on average over the same horizon. This is a reverse DCF: it holds our cash-flow model's other inputs and solves for the revenue growth that makes the model equal today's price of $82.52. A model estimate, not investment advice.
CRH (CRH) insider trading
We have no recent SEC Form 4 insider filings on file for CRH plc (CRH). Form 4 covers US-listed companies only.